Pharmaron Beijing Co., Ltd. (SZSE:300759) agreed to acquire 3.08% stake in Wuxi Biortus Biosciences Co. Ltd. from Jiangyin Baiao Management Consulting Enterprise (Limited Partnership), Jiangyin Baisheng Management Consulting Center (Limited Partnership), Jiangyin Baichuang Management Consulting Center (Limited Partnership) and Jiangyin Baiying Management Consulting Center (Limited Partnership), Wu Jiaquan for CNY 27.2 million on October 28, 2025. A cash consideration of CNY 27.21 million will be paid by Pharmaron Beijing Co., Ltd. As part of consideration, CNY 27.21 million is paid towards common equity of Wuxi Biortus Biosciences Co. Ltd. Before completion, Jiangyin Baiao Management Consulting Enterprise (Limited Partnership) owned 11.41% stake, Wu Jiaquan owns 5.73% stake, Jiangyin Baisheng Management Consulting Center owns 2.21% stake, Jiangyin Baichuang Management Consulting Center owns 0.61% stake, Jiangyin Baiying Management Consulting Center owns 0.59% stake in Wuxi Biortus Biosciences Co. Ltd. After completion, Jiangyin Baiao Management Consulting Enterprise will hold 9.7% stake, Jiangyin Baisheng Management Consulting Center will hold 1.88% stake, Jiangyin Baichuang Management Consulting Center will hold 0.52% stake, Jiangyin Baiying Management Consulting Center will hold 0.5% stake. Pharmaron Beijing Co., Ltd. (SZSE:300759) entered three agreements to acquire 82.54% stake in Wuxi Biortus Biosciences Co. Ltd. from different sellers for a combined deal value of CNY 1.4 billion. Pharmaron Beijing Co., Ltd. intends to fund the consideration by bank loans (not less than 50%) and internal funds.
As of September 30, 2025, Wuxi Biortus Biosciences Co. Ltd. reported total assets of CNY 671.56 million and total common equity of CNY 608.39 million.
The transaction is subject to consummation of due diligence investigation. The deal is approved by board of Pharmaron Beijing Co., Ltd.
Pharmaron Beijing Co. is specialised in the research, development and manufacturing of small molecule drugs, cell therapies and gene therapies. Net sales break down by activity as follows:
- laboratory services (61.3%);
- development and production of chemical processes and formulations (23.5%);
- clinical research services (12.8%);
- other (2.4%);
Net sales are distributed geographically as follows: China (17.1%), Asia (2.6%), North America (64.2%), Europe (15.6%) and other (0.5%).
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
